|
Synonyms: MABp1 | RA-18C3 | Xilonix® (proposed trade name)
Compound class:
Antibody
Comment: Bermekimab (MABp1, Xilonix) is an investigational fully human monoclonal antibody targeting IL-1α, with potential antiinflammatory action. This antibody is the first genuinely human monoclonal antibody to be produced directly from an affinity matured, human immune response. As MABp1 has not been subject to in vitro sequence modification it is predicted to have improved tolerability compared to antibodies that are 'humanised'.
A patent search suggests that Xilonix is the subject of WO2009148575 [3]. |
| References |
|
1. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM et al.. (2014)
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol, 15 (6): 656-66. [PMID:24746841] |
|
2. Ma JD, Heavey SF, Revta C, Roeland EJ. (2014)
Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther, 14 (8): 1113-20. [PMID:24707881] |
|
3. Simard J. (2009)
Interleukin-1 alpha abs and methods of use. Patent number: WO2009148575 A1. Assignee: Xbiotech, Inc.. Priority date: 30/05/2008. Publication date: 10/12/2009. |
|
4. Simard J. (2010)
TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES. Patent number: US20100040574 A1. Assignee: Xbiotech Inc.. Priority date: 22/05/2006. Publication date: 18/02/2010. |
